Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 9:06 PM
Ignite Modification Date:
2025-12-25 @ 6:57 PM
NCT ID:
NCT02566304
Group ID:
EG000
Title:
RIC HSCT, GVHD Prophylaxis
Description:
RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -6.
TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.
GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD.
Fludarabine: Given IV
Total-Body Irradiation: Undergo TBI
T Cell-Depleted Donor Lymphocyte Infusion: Undergo DLI
Cyclophosphamide: Given IV
Peripheral Blood Stem Cell Transplantation: Undergo PBSC transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo PBSC transplant
Tacrolimus: Given PO
Mycophenolate mofetil: Given IV
Laboratory Biomarker Analysis: Correlative studies
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
10
Serious Number At Risk:
35
Other Number Affected:
33
Other Number At Risk:
35
Study:
NCT02566304
Results Section:
NCT02566304
Adverse Events Module:
NCT02566304